thirty-two patients with advanced , inoperable nonhematologic soft-tissue and osseous sarcomas were treated with methyl ccnu administered via controlled intravenous infusion in doses of 130-170 mg/m2 every 6 weeks in a phase ii trial .
C0225317
soft-tissue
C1704327
osseous sarcomas